The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...

CollPlant Biotechnologies , or 'CollPlant', a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue ...

About Allergan Aesthetics At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes ...

Talk to your doctor about other complications. At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other stocks. Jim Cramer, the host of Mad Money, on Tuesday, took a close look at President Donald ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting off on a very different note. According to iSpot.TV’s analysis of ...

The US competition regulator has finally approved the $63 billion takeover of Allergan by AbbVie, but only by the slimmest of margins in a split vote. The Federal Trade Commission (FTC ...

Instead of boosting adherence to AbbVie’s products, the company saw aesthetics product sales decline 4.4% year over year to $1.3 billion in the fourth quarter. Carrie Strom, president of Global ...

AbbVie, and president, Global Allergan Aesthetics. Before we get started, I'll note that some statements we make today may be considered forward-looking statements based on our current expectations.